Shaily Engineering Plastics reported a robust FY26 performance with revenue up 25.91% to Rs 990.67 crore and net profit rising 82.5% to Rs 169.91 crore. The surge was driven by a 139% jump in healthcare revenue, which now constitutes 40% of the total business. The company also announced plans to raise up to Rs 500 crore to fund expansion and secured a Rs 423 crore order for pen injectors, signaling a shift toward higher-value manufacturing in healthcare and electronics.
Shaily Engineering Plastics FY26 Profit Soars 82.5% to Rs 169.91 Cr
Revenue increased by 25.91% to Rs 990.67 Cr; EBITDA margins expanded by 630 bps to 29%.
Reader Takeaway: Healthcare segment pivot drives massive profit growth, balanced against soft demand in legacy home furnishings business.
What just happened
Shaily Engineering Plastics Limited has posted a strong financial performance for FY 2025-26. The company saw net profit surge 82.5% to Rs 169.91 crore. Revenue grew 25.91% YoY, while EBITDA margins climbed significantly to 29%. A key highlight is the Return on Capital Employed (ROCE) which improved to 35.8%, up from 24.4% in the previous year.
Why this matters
The company is successfully executing a strategic shift toward high-margin healthcare solutions, which grew 139% to Rs 392.8 crore this year. This segment now represents 40% of total revenue. Simultaneously, the company is diversifying into consumer electronics and semiconductor chip trays, reducing reliance on legacy consumer segments that faced geopolitical headwinds in Europe and the US.
Strategic Developments
Shaily has secured a major Rs 423 crore supply agreement for pen injectors, to be executed over the next four years. To capitalize on the rising demand for GLP-1 therapies, the company commissioned a new 25 million-unit pen-injector production line in March 2026. The board has also approved an enabling resolution to raise up to Rs 500 crore to accelerate future growth projects.
Risks to watch
While the healthcare business is booming, the company's consumer division revenue declined 9% due to softer demand in Western markets and Middle East geopolitical issues. Monitoring the pace of new customer acquisitions in the semiconductor and electronics space remains crucial as these are long-cycle ventures.
What to track next
Investors should look for updates on the supply ramp-up for the new semiconductor chip tray venture scheduled for Q4 FY 26-27 and progress on the large-scale device contract discussions with global pharmaceutical innovators.